These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center. Tenold ME; Moskoff BN; Krishnan R; Rosenberg AS; Hoeg RT; Abedi M; Tuscano JM; Jonas BA Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e611-e618. PubMed ID: 33811007 [TBL] [Abstract][Full Text] [Related]
8. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. Martínez-Cuadrón D; Boluda B; Martínez P; Bergua J; Rodríguez-Veiga R; Esteve J; Vives S; Serrano J; Vidriales B; Salamero O; Cordón L; Sempere A; Jiménez-Ubieto A; Prieto-Delgado J; Díaz-Beyá M; Garrido A; Benavente C; Pérez-Simón JA; Moscardó F; Sanz MA; Montesinos P; Ann Hematol; 2018 May; 97(5):763-772. PubMed ID: 29392425 [TBL] [Abstract][Full Text] [Related]
9. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301 [TBL] [Abstract][Full Text] [Related]
10. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory Short NJ; Daver N; Dinardo CD; Kadia T; Nasr LF; Macaron W; Yilmaz M; Borthakur G; Montalban-Bravo G; Garcia-Manero G; Issa GC; Chien KS; Jabbour E; Nasnas C; Huang X; Qiao W; Matthews J; Stojanik CJ; Patel KP; Abramova R; Thankachan J; Konopleva M; Kantarjian H; Ravandi F J Clin Oncol; 2024 May; 42(13):1499-1508. PubMed ID: 38277619 [TBL] [Abstract][Full Text] [Related]
11. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. Martínez Sánchez MP; Megías-Vericat JE; Rodríguez-Veiga R; Vives S; Bergua JM; Torrent A; Suárez-Varela S; Boluda B; Martínez-López J; Cano-Ferri I; Acuña-Cruz E; Torres-Miñana L; Martín-Herreros B; Serrano A; Sempere A; Barragán E; Sargas C; Sanz M; Martínez-Cuadrón D; Montesinos P; Ann Hematol; 2021 Jun; 100(6):1497-1508. PubMed ID: 33914097 [TBL] [Abstract][Full Text] [Related]
12. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis. Huang R; He H; Xu X; Lin X; Dong Y; Wang X; Jiang F; Huang P; Mo S; Huang Z; Wang Y; Tao H; Zheng Y; Wu M; Yang C; Zheng Z; Zhao Y; Zhang Y; Li Y Cancer; 2024 Jul; 130(14):2472-2481. PubMed ID: 38470375 [TBL] [Abstract][Full Text] [Related]
13. Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. Zucenka A; Vaitekenaite V; Maneikis K; Davainis L; Pileckyte R; Trociukas I; Peceliunas V; Zvirblis T; Staras V; Griskevicius L Bone Marrow Transplant; 2021 Nov; 56(11):2804-2812. PubMed ID: 34274954 [TBL] [Abstract][Full Text] [Related]
14. A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; García R; García-Huerta AJ; Barrios M; Benavente C; Pérez-Encinas M; Simiele A; Rodríguez-Macias G; Herrera-Puente P; Rodríguez-Veiga R; Martínez-Sánchez MP; Amador-Barciela ML; Riaza-Grau R; Sanz MA; Br J Haematol; 2016 Sep; 174(5):700-10. PubMed ID: 27118319 [TBL] [Abstract][Full Text] [Related]
15. The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia. Lee SR; Yang DH; Ahn JS; Kim YK; Lee JJ; Choi YJ; Shin HJ; Chung JS; Cho YY; Chae YS; Kim JG; Sohn SK; Kim HJ J Korean Med Sci; 2009 Jun; 24(3):498-503. PubMed ID: 19543516 [TBL] [Abstract][Full Text] [Related]
16. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study. Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488 [TBL] [Abstract][Full Text] [Related]
18. FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients. Delia M; Pastore D; Carluccio P; Pasciolla C; Ricco A; Rossi AR; Casieri P; Mestice A; Albano F; Specchia G Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):767-773. PubMed ID: 28864170 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review. Sherban A; Fredman D; Shimony S; Yeshurun M; Raanani P; Stahl M; Gafter-Gvili A; Wolach O Leuk Res; 2023 Oct; 133():107368. PubMed ID: 37598660 [TBL] [Abstract][Full Text] [Related]
20. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study]. Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]